MedTrace Logo

RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

NCT07187570 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1600

Last updated 2025-09-23

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is:

• Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation?

Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation.

Persons with atrial fibrillation who are planned for an electric cardioversion will:

* Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days
* Undergo a planned electric cardioversion of the atrial fibrillation
* Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days

Conditions

  • Atrial Fibrillation (AF)

Interventions

DRUG

Dapagliflozin 10 mg once daily

Tablet Dapagliflozin 10 mg orally during from randomization for maximum 56 days.

Sponsors & Collaborators

Principal Investigators

  • Karolina Szummer, MD PhD · Karolinska Institutet

  • Ziad Hijazi, MD PhD · Dept. of Medical Sciences, Uppsala University, Uppsala, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-03
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07187570 on ClinicalTrials.gov